Wedbush reiterates Tesla stock rating on chip factory plans

Wedbush kept an Outperform rating and $600 price target on Tesla while the stock trades at $383.98 (down 15% YTD); Wedbush and Musk announced two planned Terafab chip factories in Austin targeting ~1 terrawatt annually to support Tesla AI and robotaxi ambitions, though timeline is uncertain. Stifel reiterated Buy, citing a 20.1% gross margin in Q4 2025 despite >$500M in tariff impacts, while NHTSA upgraded its FSD probe to a detailed engineering analysis covering ~3.2M vehicles and GLJ Research maintained a Sell. Barclays and Morgan Stanley hold Equalweight, with Barclays warning capex could exceed the prior $20B estimate; Wedbush also flagged a possible Tesla–SpaceX combination by 2027 as a strategic endpoint.

Analysis

A strategic move by a large OEM to own chip production changes bargaining dynamics across the semiconductor stack: foundries lose pricing power on OEM-dedicated volume while equipment, materials and OSAT suppliers capture a larger share of incremental margin. Expect a bifurcation where advanced-node pure-play foundries still command scarcity rents for leading-edge logic, but mid/near-node accelerators and packaging suppliers gain outsized growth as OEMs optimize for specialized AI accelerators rather than generic wafer volumes.

Key risks are execution and supply-side gating. Fab builds classically suffer 12–36 month yield ramps and 20–40% capex overruns; combined with potential export controls on extreme-edge toolsets, any plan to vertically integrate will be heavily path-dependent. Regulatory outcomes tied to autonomous features create asymmetric downside: a safety-driven recall or fleet grounding can compress the equity multiple long before any hypothetical revenue from robotaxi-scale learning materializes.

The market consensus is anchored on headline verticalization and eventual synergies, but it underestimates two things: (1) owning fabs does not obviate node access constraints for bleeding-edge geometries — that still flows through a tiny supplier set, and (2) the most immediate beneficiaries are likely to be equipment, substrate and packaging specialists plus local power/utility capacity providers, not necessarily incumbent foundries. That mismatch creates actionable relative-value opportunities and suggests option-based exposure to the OEM is the prudent path to capture upside while limiting tail losses.

Key Decisions for Investors

• Pair trade (12 months): Short TSM via a small notional short (or buy 6–12m puts) and go long LRCX (or AMAT) machinery exposure. Thesis: structural OEM verticalization trims TSM’s addressable share while equipment makers benefit from new fab spending. Target: 15–25% relative outperformance; stop-loss: if TSM outperforms LRCX by >10% in 3 months (cut to limit crowding risk).
• Optionality play on the OEM (18–24 months): Buy a long-dated call spread on TSLA (buy 18–24m OTM calls, sell higher-strike calls) financed by selling short-dated calls (3–6m). Rationale: captures multi-year upside from AI/robotics milestones while funding premium via near-term theta. Risk/reward: max loss = net premium (limited), upside multi-x if key milestones/partner supply announcements arrive within 12–24 months.
• Downside protection (6–9 months): Buy a TSLA put spread centered around regulatory event windows (buy deeper OTM put, sell cheaper further OTM put) to hedge recall/engineering-analysis tail risk. Cost-effective hedge that caps headline downside while retaining some upside participation if the regulatory outcome is benign.
• Infrastructure/OSAT exposure (6–18 months): Accumulate AMAT (or KLAC) to capture increased onshore fab and advanced packaging demand; take profits on a 20–30% move. Tail risk: broader capex pullback will hit equipment names — use trailing stops or put protection sized to a 10–12% drawdown.